1---2name: draft-industry-summary-s023task_id: corporate-ma/draft-industry-summary/scenario-024description: Guides preparation of an industry and market analysis memo for a diagnostics acquisition by cross-checking sell-side and independent data, quantifying reimbursement-driven financial impact, flagging customer concentration with imminent contract expiration, and providing a recency-adjusted precedent transaction multiple.5activates_for: [planner, solver, checker]6metadata:7 source: https://skillmd.com/skills/finchipaiorg/draft-industry-summary-s028---910# Skill: Draft Industry Summary Memo for Diagnostics Acquisition1112## 1. Subject-matter triage1314- Treat the assignment as a cross-source diligence memo, not a pure market overview.15- Separate core market facts from deal-specific risks, then reconcile sell-side claims against independent research and internal strategy notes.16- If the source set includes multiple markets, product lines, geographies, payor regimes, or transaction comps, enumerate them first and analyze each separately rather than blending them into one blended conclusion.17- If only one relevant customer, reimbursement event, regulatory regime, or comp set exists, state that explicitly and explain why no broader set is in scope.1819## 2. Failure modes the skill is correcting2021- Repeating sell-side market sizing, share, or growth claims without checking the base year, methodology, or independent confirmation.22- Treating an apparent market leader or high-growth segment as verified when the underlying source data are stale, selectively framed, or measured on inconsistent bases.23- Ignoring customer concentration when a major relationship is near renewal or expiration during the deal timeline.24- Describing reimbursement cuts, regulatory change, or certification delays qualitatively without translating them into financial impact.25- Assuming pipeline revenue as if early-stage products were near-commercial or fully de-risked.26- Using precedent transactions mechanically when older or atypical deals distort the median.27- Missing discrepancies between external materials and internal strategy documents on international revenue or OTC growth.2829## 3. Legal frameworks / domain conventions that apply3031- Customer concentration and renewal risk are material diligence points in healthcare diagnostics; identify the customer, the revenue exposure, the contract timing, and the transaction-window overlap, then explain the revenue and closing implications.32- Reimbursement reductions should be translated into revenue and EBITDA impact using the applicable revenue base and any documented offsetting cost changes; do not leave the effect at the narrative level.33- Laboratory-developed test regulatory change should be analyzed in light of the governing rule, any legal challenges, and any phased implementation; near-term impact may be overstated if compliance ramps gradually.34- EU in vitro diagnostics certification constraints should be assessed against the applicable conformity-assessment regime and the capacity of third-party reviewers; revenue forecasts that depend on new certification should be timing-risk adjusted.35- Recency-sensitive precedent transaction analysis should separate older or outlier deals from the relevant current market set and present both the unadjusted and adjusted benchmark where the difference is material.36- Pipeline products must be described at their actual development stage; feasibility-stage products are pre-commercial and should not be treated as near-term revenue with certainty.37- Any legal or regulatory conclusion must identify the governing authority, rule, or regulation relied on, rather than stating the conclusion in shorthand.3839## 4. Analytical scaffolds4041- Start by mapping the source set into: market data, customer and commercial contracts, reimbursement and regulatory items, pipeline and product development, precedent transactions, and any internal-versus-external inconsistencies.42- For market size and growth:43 - identify the base year used by the sell-side materials;44 - compare the stated figures to independent research;45 - note whether differences are methodological, timing-based, or substantive.46- For market share:47 - compare the stated share with independent sources;48 - state both figures and assess which is more credible and why.49- For customer concentration:50 - identify the largest customer relationships and the share of revenue they represent;51 - flag any contract expiring during or shortly after the contemplated transaction period;52 - explain the revenue exposure and any negotiating leverage or retention risk.53- For reimbursement changes:54 - identify each rate adjustment and the affected revenue base;55 - show the annual revenue effect and the resulting EBITDA effect after any offsets disclosed in the source materials.56- For laboratory-developed test change:57 - identify the governing rule and any litigation or implementation phase;58 - assess whether the timing makes the near-term impact smaller than the headline suggests.59- For EU certification risk:60 - determine whether current or pipeline products need additional certification;61 - assess the probability and timing risk associated with constrained review capacity.62- For precedent transactions:63 - identify older or unusual deals that may inflate the median;64 - present an adjusted benchmark alongside the unadjusted one and explain the valuation implication.65- For pipeline products:66 - state the actual development stage;67 - align commercialization timing to that stage;68 - discount revenue expectations where success is still uncertain.69- For OTC growth:70 - test whether recent volume growth appears durable or tied to one-time demand, stocking, or channel effects.71- Where the source materials conflict, prefer the more current, more directly supported, and methodologically consistent source, but explain the reconciliation rather than silently choosing one.7273## 5. Vertical / structural / temporal relationships7475- Track how commercial concentration, reimbursement pressure, and regulatory timing interact across the deal timeline.76- Distinguish immediate, near-term, and longer-dated impacts so that a risk with delayed effect is not presented as an immediate earnings hit.77- When a customer renewal, reimbursement cut, or certification delay overlaps with the expected closing or integration window, state the timing overlap and the practical consequence.78- If the source materials contain both external market data and internal planning assumptions, flag any divergence by topic and explain whether the gap is material or cosmetic.79- If multiple products or geographies are involved, compare them on the same basis before drawing a portfolio-level conclusion.8081## 6. Output structure conventions8283- Write the deliverable as an industry and market analysis memo with sectioned discussion by topic.84- Include a compact market data comparison table showing sell-side figure, independent figure, and a short assessment.85- Include a customer concentration section that identifies the relevant customer exposure and any near-term contract timing issue.86- Include a regulatory and reimbursement section that translates headline items into financial impact where possible.87- Include a precedent transactions section that states both the raw and recency-adjusted valuation benchmark when needed.88- Include a short section on pipeline and commercialization risk that ties product stage to revenue realism.89- End with a concise recommendations section that turns the diligence findings into action items for the investment committee or deal team, assigning each item to a responsible role and timing it to the deal process.90- Keep the memo analytical and source-based; do not pad with generic industry background that does not inform the acquisition decision.